Therapeutics News and Research

RSS

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.

12 Oct 2012

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Timothy Henry, M.D. of the Minneapolis Heart Institute Foundation treated the first patient in the ATHENA study, injecting the patient's own stem cells into the heart to restore blood flow and help regenerate heart muscle. Henry, the Foundation's Director of Research is co-principal investigator of the ATHENA study sponsored by Cytori Therapeutics.

12 Oct 2012

NYSCF conference to discuss latest advances in stem cell research

Leaders in translational stem cell research from across the country and around the world will present findings on how advances in stem cell science lead to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Seventh Annual Translational Stem Cell Research Conference, held at The Rockefeller University in Manhattan on October 10-11.

11 Oct 2012

S100A1 protein critical for endothelial cell function in ischemic angiogenesis

Restoring diminished levels of a protein shown to prevent and reverse heart failure damage could also have therapeutic applications for patients with critical limb ischemia (CLI), suggests a new preclinical study published online October 9 in Circulation Research from researchers at the Center for Translational Medicine at Thomas Jefferson University.

11 Oct 2012

Study finds how MAIT cells recognize products of vitamin B synthesis from bacteria and yeast

An Australian research team has discovered how specialised immune cells recognise products of vitamin B synthesis that are unique to bacteria and yeast, triggering the body to fight infection.

11 Oct 2012

New drug candidate improves cognitive function of rats with Alzheimer's-like mental impairment

Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.

11 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

Study identifies cellular adhesion molecules key to cancer metastasis

Although tumor metastasis causes about 90 percent of cancer deaths, the exact mechanism that allows cancer cells to spread from one part of the body to another is not well understood. One key question is how tumor cells detach from the structural elements that normally hold tissues in place, then reattach themselves in a new site.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Soluble Therapeutics to introduce high-throughput second viral coefficient determination system

Birmingham-based Soluble Therapeutics, Inc, today announced the official launch of its high-throughput second viral coefficient determination system, HSC Technology, at the IBC BioProcess International Conference in Providence, RI October 8-12.

9 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

6 Oct 2012

RXi receives SBIR grant to enable discovery and preclinical development of sd-rxRNAs

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

5 Oct 2012

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).

4 Oct 2012

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.

4 Oct 2012

UCSF to create first implantable device for patients with kidney failure

A $750,000 gift from the John and Marcia Goldman Foundation is spurring a UCSF-led effort to create the first implantable artificial kidney for patients with kidney failure.

3 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Therapeutics News and Research

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

NYSCF conference to discuss latest advances in stem cell research

S100A1 protein critical for endothelial cell function in ischemic angiogenesis

Study finds how MAIT cells recognize products of vitamin B synthesis from bacteria and yeast

New drug candidate improves cognitive function of rats with Alzheimer's-like mental impairment

PARP-1 plays a major role in controlling AR function in prostate cancer patients

Study identifies cellular adhesion molecules key to cancer metastasis

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Soluble Therapeutics to introduce high-throughput second viral coefficient determination system

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

RXi receives SBIR grant to enable discovery and preclinical development of sd-rxRNAs

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Cellectis, Medicago complete first step in therapeutic protein research collaboration

UCSF to create first implantable device for patients with kidney failure

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News